PCUTT115
OVERVIEW OF ACTIVITY
Prostate cancer (PC) is the most frequently diagnosed cancer in men, with an estimated 241,740 new cases every year in the United States. Emerging data increasingly allow individualized treatment decision-making for localized PC, including the option of active surveillance and radiation therapy for those with high-risk disease after prostatectomy. In addition, while virtually all locally advanced or metastatic sites of tumor are initially reliant on androgen stimulation for growth and respond to treatment with androgen deprivation therapy, resistance to hormone blockade inevitably develops, culminating in the recurrence of highly aggressive castration-resistant PC (CRPC). Recently published randomized, controlled studies have signaled the emergence of novel therapeutic strategies for patients with CRPC. This has led to a paradigm shift in the multidisciplinary care of patients with this disease. The treatment landscape and available options for PC have thus broadened, making choices more challenging for many healthcare professionals and patients, and a once stagnant systemic treatment algorithm, largely confined to medical or surgical castration, has evolved into delivery of cutting-edge antineoplastic therapy necessitating learning opportunities for urologists and medical oncologists. This CME program uses a roundtable discussion with leading PC investigators to assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Badani — Contracted Research: Genomic Health Inc. Dr Dreicer — Advisory Committee: Astellas Scientific and Medical Affairs Inc, Janssen Biotech Inc, Med-Direct International Ltd, Merck, Roche Laboratories Inc, Takeda Oncology. Dr Gomella — Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Biotech Inc, MDxHealth. Dr Petrylak — Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi, Takeda Oncology; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc. Dr Sartor — Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Progenics Pharmaceuticals Inc, Sanofi, Takeda Oncology. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc/Medivation Inc, Genomic Health Inc and Teva Oncology.
Hardware/Software Requirements: Last review date: June 2015
|